PROSPECTUS
Fred's, Inc.
Class A Common Stock
(no par value)
500,000 Shares
The 500,000 shares of our Class A Common Stock described in this Prospectus
will be offered for sale from time to time. The Common Stock offered may (i) be
sold by us in the public market, in which case, we will receive all proceeds
from any sale of Common Stock, (ii) be used as consideration in the acquisition
of assets, goods, or services for use or sale in the conduct of our business and
then be resold by the providers of such assets, goods or services, or (iii) be
issued pursuant to the conversion of preferred stock in accordance with our
Charter. Alternatively, the Common Stock may be offered to or through
broker-dealers or underwriters who may act solely as agents, or who may acquire
Common Stock as principals. The distribution of the Common Stock being offered
may be effected in one or more transactions that may take place through the
NASDAQ National Market System, including block trades or ordinary broker's
transactions, through privately negotiated transactions, through an underwritten
public offering or through a combination of any such methods of sale, at market
prices prevailing at the time of sale, at prices related to such prevailing
market prices or at negotiated prices. We may pay usual and customary or
specifically negotiated brokerage fees or commissions in connection with sales
of the Common Stock. See "Plan of Distribution." We will pay all expenses (other
than commissions or discounts of underwriters, broker-dealers or agents, broker
fees, state and local transfer taxes and fees and expenses of counsel or other
advisers to the purchasers) in connection with the registration of the Common
Stock being offered.
Our Common Stock is traded on the NASDAQ National Market under the symbol
"FRED". On March 14, 2002 the closing price for the Common Stock as quoted on
NASDAQ National Market was $36.37.
To the extent required, certain other information relating to the terms of
each sale of the Common Stock offered pursuant to this Prospectus, including the
applicable public offering price, the names of any underwriters, broker-dealers
or agents, the compensation, if any, of such underwriters, broker-dealers or
agents and any other terms will be set forth in an accompanying Prospectus
Supplement. The aggregate proceeds from the sale of Common Stock offered by
Fred's will be the purchase price of the Common Stock sold less the aggregate
agents' commissions and underwriters' discounts, if any, and other expenses of
issuance and distribution borne by us.
Broker-dealers, underwriters or agents that participate in the distribution
of the Common Stock may be deemed to be underwriters under the Securities Act of
1933, as amended, and any commissions received by them and any profit on the
resale of the Common Stock purchased by them might be deemed to be underwriting
discounts and commissions under the Securities Act.
See "Risk Factors" beginning on page 4 for a discussion of certain factors
that should be considered in connection with an investment in the Common Stock
offered hereby.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED THESE SECURITIES OR PASSED UPON THE
ACCURACY OF ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
The information in this prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer
to sell these securities and is not soliciting an offer to buy these securities
in any state where the offer or sale is not permitted.
The date of this Prospectus is March 14, 2002.
NO DEALER, SALESPERSON OR OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATIONS OTHER THAN THOSE CONTAINED OR
INCORPORATED BY REFERENCE IN THIS PROSPECTUS OR ANY PROSPECTUS SUPPLEMENT IN
CONNECTION WITH AN OFFER MADE BY THIS PROSPECTUS OR ANY PROSPECTUS SUPPLEMENT;
YOU MUST NOT RELY UPON ANY SUCH INFORMATION OR REPRESENTATION AS HAVING BEEN
AUTHORIZED BY FRED'S, INC.OR ANY, UNDERWRITER, DEALER OR AGENT. NEITHER THE
DELIVERY OF THIS PROSPECTUS, ANY PROSPECTUS SUPPLEMENT NOR ANY SALE MADE
HEREUNDER SHALL UNDER ANY CIRCUMSTANCES CREATE AN IMPLICATION THAT THERE HAS
BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF OR THEREOF OR
THAT THE INFORMATION CONTAINED HEREIN IS CURRENT AS OF ANY TIME SUBSEQUENT TO
THE DATE HEREOF.
AVAILABLE INFORMATION
We file annual, quarterly and special reports, proxy statements and other
information with the Securities and Exchange Commission ("SEC"). You may read
and copy any document we file at the Public Reference Room maintained by the SEC
at 450 Fifth Street N.W., Washington, D.C. 20549. Please call the Commission at
1-800-SEC-0330 for further information about the public reference room. The
Commission also maintains a Web site that contains reports, proxy and
information statements and other information regarding registrants that file
electronically with the Commission at http://www.sec.gov.
Our Common Stock is listed on the NASDAQ National Market System. Reports,
proxy and information statements, and other information concerning Fred's can be
inspected at the offices of the NASDAQ Stock Market, Inc., at 1735 K Street NW,
Washington, D.C. 20006-1500.
We have filed with the Commission a registration statement on Form S-3,
together with all amendments and exhibits thereto, under the Securities Act
covering the shares of Common Stock offered hereby. As permitted by the SEC,
this Prospectus does not contain all of the information set forth in the
Registration Statement. Copies of the Registration Statement are available from
the Commission as set forth above.
DOCUMENTS INCORPORATED BY REFERENCE
We hereby incorporate by reference in this Prospectus our:
* Annual Report on Form 10-K, excluding financial statements for the fiscal
year ended February 3, 2001;
* Our Quarterly Reports on Form 10-Q for the quarterly periods ended May 5,
2001, August 4, 2001 and November 3, 2001, and our Quarterly Report on Form
10-Q/A for the quarterly period ended August 4, 2001; and
* Our Current Reports on Form 8-K on March 29, 2001, June 5, 2001 as
amended, September 6, 2001 and March 6, 2002; and
* Our Financial Statements included in the Pre-Effective Amendment No. 2 to
Fred's Registration Statement on Form S-3 (Registration Number 333-68478) filed
with the Securities Exchange Commission on September 20, 2002.
* The description of our Common Stock contained in the Registration
Statement on Form 10 filed with the Securities and Exchange Commission on May
15, 1991 as updated by the description of our preferred stock purchase rights in
the Registration Statement on Form 8-A relating filed on October 21, 1998.
We also incorporate by reference any reports that we will file with the SEC
pursuant to Section 13(a) 13(c), 14 or 15(d) of the Securities Exchange Act
after the date of this Prospectus but before all of the common stock offered by
this Prospectus has been sold. Any statement contained in a document
incorporated by reference shall be deemed to be modified or superseded for
purposes of this Prospectus to the extent that a statement contained in this
Prospectus modifies or supersedes such statement. Any such statement so modified
or superseded shall not be deemed, except as so modified or superseded, to
constitute a part of this Prospectus.
We will provide without charge to each person to whom this Prospectus is
delivered, upon written or oral request of any such person, a copy of any and
all of the information that has been incorporated by reference in this
Prospectus (excluding exhibits to the information that is incorporated by
reference unless such exhibits are themselves specifically incorporated by
reference). Please direct such requests to Charles S. Vail, Secretary, Fred's,
Inc., 4300 New Getwell Road, Memphis, Tennessee, 38118, telephone number (901)
365-8880.
THE COMPANY
Fred's, Inc., founded in 1947, operates 379 discount general merchandise
stores, including 26 franchised Fred's stores, in 11 states primarily in the
southeastern United States. 202 of our stores have full service pharmacies. Our
stores offer the convenience of a small-format discount retailer or drug store,
but typically offer a broader selection of merchandise.
Our stores stock over 12,000 frequently purchased items which address the
everyday needs of our customers, including household goods, apparel, health and
beauty aids, food, tobacco and cleaning supplies. In addition to nationally
recognized brand name products, our merchandise includes private label products
and, to a lesser extent, opportunistic buys. At an average of approximately
15,000 square feet, our stores are smaller than those of a mass merchant
(typically over 100,000 square feet), but larger than a small-format discount or
dollar store (typically under 10,000 square feet). We believe our customers shop
at Fred's stores for our convenient locations, merchandise assortment,
competitive prices and advertised promotions.
Our principal executive office is located at 4300 New Getwell Road,
Memphis, Tennessee, 38118 telephone (901) 365-8880. Our web site is located at
http://www.fredsinc.com. "Fred's" is also used to refer to all of the wholly
owned subsidiaries of Fred's, Inc.
RISK FACTORS
You should carefully consider the following risks, as well as the other
information contained in this Prospectus and any applicable Prospectus
Supplement, before investing in shares of our common stock. If any of the
following risks actually occur, our business could be harmed. In that case, the
trading price of the common stock could decline, and you might lose all or part
of your investment.
* We may not be able to successfully execute our expansion plan.
The growth of our net sales and earnings will depend in part on our ability
to expand our operations through the opening of new stores in existing and new
markets and to operate those stores profitably. We have grown rapidly primarily
through opening new stores, some of which include a pharmacy. We may not be able
to open all of the stores contemplated by our growth strategy, and new stores
that we open may not be profitable. A significant growth area for us has been
our pharmacy business. Our primary mechanism for adding new pharmacies is
through the acquisition of prescription files from independent pharmacies. The
availability of pharmacy file acquisition candidates in our targeted expansion
areas may be limited and will depend on a variety of factors.
Our operating complexity and management responsibilities have increased,
and will continue to increase, as we grow. Our growth also requires that we
continue to expand and improve our operating and financial systems and to
expand, train and manage our employee base. In addition, as we continue to open
or acquire new stores, we may be unable to hire a sufficient number of qualified
store personnel or successfully integrate the stores into our business.
Our expansion prospects also depend on a number of other factors, many of
which are out of our control, including, among other things:
* general and local economic conditions;
* acceptance of the Fred's concept in particular markets; competition;
* consumer preferences;
* financing and working capital requirements;
* our ability to provide adequate distribution capabilities as well as
the costs and risks associated with the potential need to construct
additional distribution facilities to support growth;
* our ability to negotiate store leases on favorable terms;
* our ability to improve costs and timing associated with opening new
locations; and
* availability of quantities of close out or special situation products.
Failure to realize these growth plans could be detrimental to our goals of
increasing market share and increasing same store revenues. Additionally, we
cannot assure you that our newly opened stores will not adversely affect the
revenues and profitability of our existing stores.
* We depend on key personnel and may not be able to retain these employees or
recruit additional qualified personnel, which would harm our business.
Our success depends to a large extent on the continued service of our
executive management team. Departures by our executive officers could have a
negative impact on our business, as we may not be able to find suitable
management personnel to replace departing executives on a timely basis. We do
not maintain key-man life insurance on any of our executive officers.
In addition, as our business expands, we believe that our future success
will depend greatly on our continued ability to attract and retain highly
skilled and qualified personnel. Recently, competition for qualified pharmacists
and other pharmacy professionals has been especially strong. Although we
generally have been able to meet our staffing requirements in the past, our
inability to do so in the future at costs that are favorable to us, or at all,
could impair our ability to increase revenue, and our customers could experience
lower levels of customer care.
* We may not be able to achieve comparable store sales gains in the future.
A variety of factors affect our comparable store sales results, including:
* economic conditions;
* the retail sales environment;
* the availability and cost of credit from vendors;
* the results of our merchandising strategies;
* the success of our marketing and promotional programs; and
* our ability to otherwise execute our business strategy.
There can be no assurance that we will continue to achieve comparable store
sales gains. Our comparable store sales results could cause the price of our
common stock to fluctuate substantially.
We face significant competition in our markets.
We operate in highly competitive markets. In our markets, we compete
against national, regional and local discount or dollar store retailers, chain
drug stores, supermarkets, combination food and drug stores, discount general
merchandise stores, mass merchandisers, independent drug stores and local
merchants. In addition, other chain stores may enter our markets and become
significant competitors in the future. Many of our competitors have greater
financial resources than we do. Economic pressures on or bankruptcies of vendors
or competitors could result in increased pricing pressures. This competition
could adversely affect our results of operations and financial condition in the
future. In addition to competition from the discount retail and drug store
chains, our pharmacy business also competes with hospitals, health maintenance
organizations, mail order and internet-based prescription drug providers. Our
stores compete, among other things, on the basis of convenience of location and
store layout, product mix and selection, customer convenience and price.
* We require a significant amount of cash flow from operations and third party
financing to expand our business in accordance with our growth strategy and to
fund our other liquidity needs.
We cannot assure you that we will be able to generate sufficient cash flow
from operations or that future borrowings will be available to us under our
existing credit agreement in an amount adequate to grow our business as
currently planned and to fund our other liquidity needs. We spent approximately
$17.4 million in fiscal 2001 on capital expenditures, primarily for new and
replacement stores, and, in addition, we spent approximately $1.6 million in
fiscal 2001 for lease and pharmacy customer file acquisition costs. We also
require working capital to support inventory for our existing stores. Failure to
generate or raise sufficient funds may require us to modify, delay or abandon
some of our future growth or expenditure plans. Also, our results would be
adversely affected if interest rates increase from present levels.
* We would be materially and adversely affected if our distribution center is
shut down.
We operate an approximately 850,000 square foot centralized distribution
center in Memphis, Tennessee. Approximately 60% of the merchandise received by
our stores in fiscal 2001 was shipped through the distribution center, with the
remainder (primarily pharmaceuticals, certain snack food items, greeting cards,
beverages and tobacco products) being shipped directly to the stores by
suppliers. If our distribution center is shut down for any reason, we could
incur significantly higher costs and longer lead times associated with
distributing our products to our stores during the time it takes for us to
reopen or replace the center. We maintain business interruption insurance to
protect us from the costs relating to matters such as a shutdown, but we cannot
assure you that our insurance will be sufficient, or that the insurance proceeds
will be timely paid to us, in the event of a shutdown.
* Our operations are subject to trends in the healthcare industry.
Pharmacy sales represent a significant and growing percentage of our total
sales. Pharmacy sales accounted for 33.9% of our net sales for fiscal 2001.
Revenues are affected by changes within the health care industry, including
changes in programs providing for reimbursement of the cost of prescription
drugs by third-party payors, such as government and private sources, and
regulatory changes relating to the approval process for prescription drugs.
Pharmacy sales generally have not only lower margins than general merchandise
sales, but are also subject to increasing margin pressure, as managed care
organizations, insurance companies, employers and other third-party payors,
which collectively we call third-party plans, become more prevalent in our
market area and as these plans continue to seek cost containment. A growing
percentage of our prescription drug volume has been accounted for by sales to
customers who are covered by third-party payment programs. Pharmacy sales to
persons covered by third-party plans accounted for 83% of our total pharmacy
sales for fiscal 2000 and 84% of our total pharmacy sales for fiscal 2001.
Although contracts with third-party payors may increase the volume of
prescription sales and gross profits, third-party payors typically reimburse us
at lower rates than those on non third-party prescriptions. Accordingly, there
has been downward pressure on gross profit margins on sales of prescription
drugs which is expected to continue in the future. Also, any substantial delays
in reimbursement, or significant reduction in coverage or payment rates from
third-party plans can have a material adverse effect on our business.
Healthcare reform initiatives of federal and state governments may also
affect our revenues from prescription drug sales. These initiatives (at both the
federal and state levels) include:
* changes in programs providing for reimbursement for the cost of
prescription drugs by third-party plans;
* proposals designed to significantly reduce spending on Medicare,
Medicaid and other government programs; and
* regulatory changes relating to the approval process for prescription
drugs.
These initiatives could lead to the enactment of federal and state
regulations that could adversely impact our prescription drug sales and,
accordingly, our results of operations. Various proposals relating to federal
prescription drug payment legislation or regulation are currently being
considered which would likely have the effect of lowering the payment or
reimbursement received by pharmacies from purchases made by persons covered by
the program.
* Our operations are subject to federal and state laws and regulations and
potential liabilities, which could adversely impact our business if changed.
Our business is subject to various federal and state regulations. For
example, we are subject to federal, state and local licensing and registration
regulations relating to, among other things, our pharmacy operations. Violations
of any of these regulations could result in various penalties, including
suspension or revocation of our licenses or registrations or monetary fines. We
are also subject to federal and state laws that require our pharmacists to offer
counseling, without additional charge, to their customers about medication,
dosage, delivery systems, common side effects and other information the
pharmacists deem significant. Our pharmacists also may have a duty to warn
customers regarding any potential negative effects of a prescription drug if the
warning could reduce or negate these effects. Additionally, we are subject to
federal Drug Enforcement Agency and state regulations relating to our pharmacy
operations, including purchasing, storing and dispensing of controlled
substances. We are also subject to various laws and regulations relating to
food, over the counter medications and other products sold by us, including
products sold by us on a private label basis. Failure to comply with such laws
or regulations or sales of products that are defective or result in injury to
people or property could adversely affect our business or profitability. Laws
governing our employee relations, including minimum wage requirements, overtime
and working conditions also impact our business. Increases in the federal
minimum wage rate, employee benefit costs or other costs associated with
employees could significantly increase our cost of operations, which could
adversely affect our level of profitability.
* We depend on our major suppliers for merchandise.
Our business is dependent upon our ability to purchase brand name and other
merchandise at competitive prices. A loss of one or more key suppliers in
certain product categories could have a material adverse effect on our business.
Although our relations with key suppliers are currently satisfactory and we have
adequate sources of brand name and other merchandise at competitive prices,
there can be no assurance that we will be able to acquire such merchandise at
comparable prices or on comparable terms in the future.
Also, we currently operate under a purchase and supply contract with one
supplier as our primary wholesaler to provide substantially all of our
prescription drugs. During fiscal 2001, approximately 95% of our total
prescription drug purchases were made from this primary pharmaceutical
wholesaler. Although there are alternative wholesalers that supply
pharmaceutical products, any unplanned loss of this supplier could have a
short-term gross margin impact on our business until an alternative wholesaler
arrangement could be implemented.
* An increase in the cost or a disruption in the flow of our imported goods may
decrease our sales and profits.
We rely on imported goods to sell in our stores. Merchandise imported
directly from overseas manufacturers and agents accounts for a portion of our
total purchases. In addition, we believe that a small portion of our goods
purchased from domestic vendors is imported. East Asia is the source of a
substantial majority of our imports. Imported goods are generally less expensive
than domestic goods and contribute significantly to our favorable profit
margins. A disruption in the flow of our imported merchandise or an increase in
the cost of those goods may decrease our sales and profits.
If imported merchandise becomes more expensive or unavailable, the
transition to alternative sources may not occur in time to meet our demands.
Products from alternative sources may also be of lesser quality and more
expensive than those we currently import. Risks associated with our use of
imported goods include disruptions in the flow of imported goods because of
factors such as raw material shortages, work stoppages, strikes and political
unrest; problems with oceanic shipping, including shipping container shortages;
economic crises and international disputes; and increases in the cost of
purchasing or shipping foreign merchandise resulting from failure of the United
States to maintain normal trade relations with source countries; import duties,
import quotas and other trade sanctions; and increases in shipping rates imposed
by the trans-Pacific shipping cartel.
Our business is affected by general economic conditions and fluctuations in
consumer confidence and spending. General economic conditions and consumer
confidence and spending can decline as a result of numerous factors outside of
our control such as terrorist attacks, acts of war and natural disasters. For
example, the terrorist attacks occurring in New York, Washington, D.C. and
Pennsylvania on September 11, 2001, have had, and we expect will continue for
some time to have a negative effect on the United States economy. While the
precise effects of these events on our industry and business are difficult to
determine, it is possible that they may have an adverse effect on our operating
and financial performance.
* Shares eligible for public sale after this offering could adversely affect our
stock price.
Sales of a substantial number of shares of our Common Stock into the public
market could adversely affect the market price of our Common Stock and could
impair our ability to raise capital in the future through an offering of our
equity securities. Upon completion of this offering, 25,367,944 shares of our
Common Stock will be outstanding and 917,205 shares of our Common Stock will be
reserved for issuance upon exercise of any options to be granted under the
Incentive Stock Option Plan. Although the 500,000 shares of Common Stock to be
sold in this offering expected are to be sold only as opportunities and needs
arise over time, from a regulatory viewpoint the shares will be immediately
eligible for sale in the public market without restriction after completion of
this offering, except shares purchased by an "affiliate," as that term is
defined under the rules and regulations of the Securities Act of 1933, as
amended.
* Our stock price may be volatile and could decline substantially.
The stock market has, from time to time, experienced extreme price and
volume fluctuations. Many factors may cause the market price for our common
stock to decline following this offering, including:
* operating results failing to meet the expectations of securities
analysts or investors in any quarter;
* downward revisions in securities analysts' estimates;
* material announcements by us or our competitors; and
* the other risk factors recited in this prospectus.
In the past, companies that have experienced volatility in the market price
of their stock have been the subject of securities class action litigation. If
we become involved in a securities class action litigation in the future, it
could result in substantial costs and diversion of management attention and
resources, thus harming our business.
* Our quarterly operating results will fluctuate due to seasonality and other
factors, and variation in quarterly results could cause the price of our common
stock to decline.
Our business is seasonal. Historically, the highest volume of sales,
working capital requirements and net income occurs during the fourth fiscal
quarter and the lowest volume occurs during the second fiscal quarter. We expect
to continue to experience fluctuations in our net sales and net income due to a
variety of factors. A shortfall in results for the fourth quarter of any fiscal
year could have a material adverse effect on our annual results of operations.
Our quarterly results of operations also may fluctuate significantly as a result
of a variety of factors including:
* the timing of new store openings;
* net sales contributed by new stores;
* increases or decreases in comparable store sales;
* timing of certain holidays;
* changes in our merchandise, general economic, industry and weather
conditions that affect consumer spending; and
* actions of our competitors.
* Provisions in our shareholder rights plan might deter acquisition bids for us.
On October 12, 1998, we adopted a Shareholders Rights Plan granting a
dividend of one preferred share purchase right for each common share
outstanding. Each share purchase right represents the right to purchase
one-hundredth of a share of preferred stock at a preset price to be exercised
when any individual, firm, corporation or other entity, including their
affiliates or associates, acquires 15% or more of the common stock then
outstanding. The share purchase rights are not exercisable by the person who
acquires 15% or more of our common stock and would dilute the interests of an
acquirer at the time of exercise. The purpose of the Shareholders Rights Plan is
to cause prospective acquirers to approach our Board of Directors before
attempting to obtain control of Fred's. The potential for dilution as a result
of the exercise of rights may deter otherwise interested parties from making
acquisition bids.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
Statements, other than those based on historical facts that we expect or
anticipate may occur in the future are forward-looking statements which are
based upon a number of assumptions concerning future conditions that may
ultimately prove to be inaccurate. Actual events and results may materially
differ from anticipated results described in such statements. Our ability to
achieve such results is subject to certain risks and uncertainties, including:
* economic and weather conditions which affect buying patterns of our
customers;
* changes in consumer spending and our ability to anticipate buying
patterns and implement appropriate inventory strategies;
* continued availability of capital and financing;
* competitive factors;
* changes in reimbursement practices for pharmaceuticals;
* governmental regulation; and
* other factors affecting business beyond our control.
Consequently, all of the forward-looking statements are qualified by these
cautionary statements and there can be no assurance that the results or
developments anticipated by us will be realized or that they will have the
expected effects on our business or operations. Actual results, performance or
achievements can differ materially from results suggested by these
forward-looking statements because of a variety of factors including those
described in the section of this prospectus entitled "Risk Factors" beginning on
page 4. We undertake no obligation to update any forward-looking statement to
reflect events or circumstances arising after the date on which it was made.
USE OF PROCEEDS
We will use any cash from the sale of Common Stock to expand or improve our
current business through purchasing additional or improving existing facilities
or capacity, or obtaining goods or services for use or sale in the conduct of
our business.
Selected Financial Data
(dollars in thousands, except per share amounts)
The statement of operations data for the five years ended February 3, 2001 have
been derived from the audited consolidated financial statements. This data has
been adjusted for the 5-for-4 stock split effected on June 18, 2001 and the
3-for-2 stock split effected on February 1, 2002.
2000(1) 1999 1998(2) 1997 1996
Statement of Income Data:
Net sales $781,249 $665,777 $600,902 $492,236 $418,297
Operating income 25,720 18,943 14,711 15,511 6,779(3)
Income before income taxes 22,494 16,439 13,605 15,660 6,508
Provision for income taxes 7,645 5,737 4,775 5,873 702
Net income 14,849 10,702 8,830 9,787 5,806
Net income per share: (4)
Basic .66 .48 .40 .45 .27
Diluted .65 .47 .39 .44 .27
Selected Operating Data:
Operating income as a percentage
of sales 3.3% 2.9% 2.4% 3.2% 1.6%3
Increase in comparable
store sales(5) 9.2%6 5.2% 5.6% 8.3% 2.2%
Stores open at end of period 320 293 283 261 213
Balance Sheet Data (at period end):
Total assets $254,795 $240,240 $220,757 $195,407 $161,148
Short-term debt
(including capital leases) 2,678 30,736 11,914 214 1,641
Long-term debt
(including capital leases) 31,705 11,761 11,821 1,368 138
Shareholders' equity 159,687 145,913 136,983 129,359 119,579
(1) Results for 2000 include 53 weeks.
(2) Results for 1998 include the effect of the 1998 adoption of LIFO for
pharmacy inventories.
(3) After $3,289 of restructuring and other charges.
(4) Adjusted for the 5-for-4 stock split effected on June 18, 2001 and the
3-for-2 stock split effected on February 1, 2002.
(5) A store is first included in thecomparable store sales calculation after
the end of the twelfth month following the store's grand opening month.
(6) The increase in comparable store sales for 2000 is computed on the same
53-week period for 1999.
PLAN OF DISTRIBUTION
The Shares offered hereunder may be sold from time to time by Fred's or by
those who have received shares of Common Stock in consideration for assets,
goods, services or upon conversion of Fred's convertible preferred stock
acquired by Fred's. Such sales may be made on NASDAQ, in the over-the-counter
market, or otherwise, at prices and on terms then prevailing or at prices
related to the then-current market price, or in negotiated transactions. The
shares may be sold to or through one or more broker-dealers, acting as agent or
principal, block trades, agency placements, exchange distributions, brokerage
transactions or otherwise, or in any combination of transactions in the public
market or may be used by Fred's as consideration in the acquisition of assets,
goods, or services for use or sale in the conduct of the Company's business and
then resold by the providers thereof, or by persons who received shares upon
conversion of Fred's convertible preferred stock.
At the time we make a particular offer of shares of Common Stock, to the
extent required, a supplement to this Prospectus will be distributed which will
identify and set forth the aggregate number of shares being offered and the
terms of the offering, including the name or names of any underwriters, dealers
or agents, the purchase price paid by any underwriter for the Shares purchased
from Fred's, any discounts, commissions and other items constituting
compensation from Fred's and any discounts, commissions or concessions allowed
or re-allowed or paid to dealers, including the proposed selling price to the
public. Such supplement to this Prospectus and, if necessary, a post-effective
amendment to the registration statement of which this Prospectus is a part, will
be filed with the Securities and Exchange Commission to reflect the disclosure
of additional information with respect to the distribution of the Shares.
Any or all of the sales or other transactions involving the shares
described above, whether effected by Fred's, any broker-dealer or others, may be
made pursuant to this prospectus. In addition, any shares that qualify for sale
pursuant to Rule 144 under the Act may be sold under Rule 144 rather than
pursuant to this Prospectus.
In order to comply with the securities laws of certain states, the shares
may be sold in such jurisdictions only through registered or licensed brokers or
dealers. In addition, in certain states the shares may not be sold unless
registered or qualified for sale or an exemption from registration or
qualification requirements is available and is complied with.
We will pay the registration and professional fees, and printing costs
associated with this registration statement.
LEGAL MATTERS
The legality of the Common Stock offered hereby will be passed upon for the
Company by Baker, Donelson, Bearman & Caldwell, PC, Memphis, Tennessee.
EXPERTS
The financial statements incorporated in this Prospectus by reference to
the Registration Statement on Form S-3 (Registration No. 333-68478), have been
so incorporated in reliance on the report of PricewaterhouseCoopers, LLP,
independent accountants, given on the authority of said firm as experts in
auditing and accounting.
Filed Under Rule 424(b)(2)
Registration Statement No. 333-83918 (effective March 14, 2002)
Prospectus Supplement Number 1
Dated Friday, March 15, 2002
to Prospectus dated March 14, 2002
98,750 SHARES
FRED'S, INC.
COMMON STOCK
-----------------------
You should read this prospectus supplement and the accompanying prospectus
carefully before you invest. Both documents contain information you should
consider when making your investment decision.
INVESTING IN FRED'S, INC. COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. SEE
"RISK FACTORS" BEGINNING ON PAGE 4 OF THE PROSPECTUS CONTAINED IN OUR
REGISTRATION STATEMENT ON FORM S-3 FILED ON MARCH 6, 2002 WHICH BECAME EFFECTIVE
ON MARCH 14, 2002 TO READ ABOUT FACTORS YOU SHOULD CONSIDER BEFORE BUYING SHARES
OF OUR COMMON STOCK.
On March 14, 2002, we sold 81,300 shares of our Common Stock to the public
under the terms of this prospectus supplement; the common stock was sold at a
price of $35.6988. On March 14, 2002, we sold 17,450 shares of our Common Stock
to the public under the terms of this prospectus supplement; the common stock
was sold at a price of $36.3283. Our common stock is traded on the Nasdaq
National Market under the symbol "FRED." On March 15, 2002, the high and low
prices for our common stock on the were $37.24 and $35.82 respectively. After
such sales, we had 25,498,434 shares of common stock issued and outstanding.
USE OF PROCEEDS
These sales were made through Morgan Keegan & Company, Inc. a registered
broker-dealer. The net proceeds to us from this offering will be $3,536,241.28.
We plan to use the net proceeds for general corporate purposes, including but
not limited to working capital.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION OR ANY OTHER STATE
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR
DETERMINED IF THIS PROSPECTUS SUPPLEMENT IS TRUTHFUL OR COMPLETE. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
----------------
The date of this prospectus supplement is March 15, 2002